Last updated: February 24, 2026
What are the primary suppliers for Avutometinib Potassium?
Avutometinib potassium (also known by its chemical name) is a targeted kinase inhibitor under clinical investigation. The supply chain is limited, with most procurement originating from specialized chemical and pharmaceutical manufacturers.
Key Suppliers
| Supplier Name |
Location |
Capabilities |
Notes |
| MSD (Merck Sharp & Dohme) |
United States |
Contract manufacturing, clinical-grade batches |
Produces investigational compounds, including Avutometinib components |
| Shanghai Medicilon |
China |
Custom synthesis, GMP manufacturing |
Capable of producing research and early-phase clinical material |
| WuXi AppTec |
China, US, Europe |
CRO, CDMO services, chemical synthesis |
Provides scale-up and GMP-grade production, including active pharmaceutical ingredients (APIs) |
| Biosynth Carbosynth |
UK, US |
Chemical synthesis and specialty chemicals |
Can supply intermediates and active forms for research and clinical stages |
Notes on Supply
- Most suppliers focus on small to mid-scale batches suitable for clinical trials.
- Full-scale commercial manufacturing remains limited; large-scale supply generally involves partnerships with major pharmaceutical manufacturers.
Who supplies Defactinib Hydrochloride?
Defactinib (PF-04554878) is a focal adhesion kinase (FAK) inhibitor used in oncology research and clinical trials. Its supply chain includes pharmaceutical manufacturers and chemical suppliers.
Key Suppliers
| Supplier Name |
Location |
Capabilities |
Notes |
| Pfizer |
United States |
Original developer, contracts out manufacturing |
Manufactures for clinical and research phases; may have licensing arrangements |
| WuXi AppTec |
China, US, Europe |
Custom synthesis, GMP manufacturing |
Produces GMP-grade material and scale-up for clinical study supply |
| MedKoo Biosciences |
US |
Fine chemicals, research supply |
Supplies research-grade Defactinib; GMP-grade may be limited |
| Dissolution Technologies |
US |
Chemical synthesis |
Capable of producing Defactinib hydrochloride for research purposes |
Notes on Supply
- Defactinib is primarily supplied for research and clinical trial use.
- Large-scale manufacturing depends on licensing arrangements with Pfizer or authorized third-party manufacturers.
- Specifications include high purity (>99%) pharmaceutical-grade material for clinical applications.
Summary of Supply Chain Dynamics
- Both Avutometinib potassium and Defactinib hydrochloride are primarily produced by contract manufacturing organizations (CMOs) specializing in chemical synthesis and GMP production.
- Major pharmaceutical companies may hold manufacturing rights or licensing agreements, influencing availability.
- Demand centers include biotech firms conducting clinical trials across multiple phases.
Key Takeaways
- Low-volume supply mostly comes from specialized CMOs in China, the US, and Europe.
- Large-scale manufacturing for commercial distribution is limited and often controlled via licensing agreements.
- Suppliers like WuXi AppTec and Biosynth Carbosynth dominate research-grade and early-phase GMP-grade provision.
- Original developers, such as Pfizer, may directly supply or license production rights.
- Supply chain transparency varies; partnerships influence availability and pricing.
FAQs
Q1: Are there authorized bulk suppliers for commercial-scale Avutometinib potassium?
A1: No. Commercial-scale production is limited; most supply occurs via licensing agreements with major pharma companies.
Q2: Can I source Defactinib hydrochloride directly from WuXi AppTec?
A2: WuXi provides GMP material for clinical trials; for commercial product, licensing or partner arrangements are typically required.
Q3: What are the typical grades of the compounds supplied?
A3: Clinical-grade compounds are standard; research-grade options are also available from multiple chemical suppliers.
Q4: Are these compounds available globally?
A4: Availability depends on regional regulations; suppliers generally ship worldwide, subject to export controls.
Q5: Are there alternatives or generic versions?
A5: Generic versions are not widely available; patent and licensing restrictions can limit this option.
References
- PubChem. (2023). Avutometinib potassium. Retrieved from https://pubchem.ncbi.nlm.nih.gov/
- PubChem. (2023). Defactinib hydrochloride. Retrieved from https://pubchem.ncbi.nlm.nih.gov/
- FDA. (2022). Guidance for Industry: Contract Manufacturing Arrangements.
- WuXi AppTec. (2023). Capabilities and services. Retrieved from https://www.wuxiapptec.com/
- Biosynth Carbosynth. (2023). Chemical synthesis offerings. Retrieved from https://www.biosynth.com/
